Blue Diamond Ventures Inc (BLDV)

[JPS02]

BLDV and Cann10 North America Synchronize Objectives

Blue Diamond Ventures Inc. will Benefit from Additional Resources

April 9th, 2018 – Blue Diamond Ventures Inc, (OTC PK: BLDV) Chicago, IL.

Cann10 North America Holdings LTD. and Blue Diamond Ventures Inc., the largest shareholder in Cann10 North America, are working toward combining their efforts in the most strategic way.

Cann10 Israel Ownership controls 51% of Cann10 North America, and the primary initial objectives include, offering Professional Medical Cannabis Education, and running the industry’s premiere Medical Cannabis Industry Conferences in North America.

“Cann10 North America & BLDV will raise money with a Tier 1 Reg A+” says Josh Alper, BLDV CEO. “As an Alternative Reporting – Pink Sheet Company – BLDV is eligible for a Reg A+ Offering, and now with the support of Cann10 NA, we can get it done” “Most of the funds raised will be used to invest in the Cann10 XL, to secure the pipeline of Cannabis Innovations and Technology from Israel, for the North America Company and some to produce the first CannX Conference in North America in 2019.

Cann10 is a Global Partner with activity in ten countries with an aggressive strategy of participating in licenses and ventures of all types, but with a long-term focus on Targeted Therapies, Specific Formulations and Medical Devices providing a bridge to the BioCannacuetical on the road to Biopharmaceutical.

Yossi Bornstein, CEO of Shizim Ltd, and Chairman of Cann10 International currently serves on the board of multiple Biotech companies including one traded on the Nasdaq, and Kobi Caspi CFO of Shizim are both expected to join the BLDV Board of Directors.

Cann10 International recognizes the potential of the public aspects of BLDV. The two years spent by the Alper Group of Companies cleaning up the books, structuring the operations and defining the offerings of the company created the conditions that will drive the effort forward.

The parties will announce further steps as they are confirmed.

About BLDV:
Blue Diamond Ventures, Inc. is a diversified customer centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in medical cannabis markets and is driven by critical thinking, the scientific method and compassionate ways to deliver sustainable results

About Cann10:
Cann10 is one of the Leading Medical Cannabis Groups in Israel. They create and produce highly recognized Professional Cannabis Education Programs, including the CannX Medical Conferences in Israel, and the Cann10 XL a focused accelerator, offering selected entrepreneurs the advantages of high quality infrastructures, facilities, team, network, know-how and professional mentoring, tailored to support successful development, fund raising and commercialization of new technologies in this emerging field.

A collaboration between a leading Israeli authorized medical cannabis farm, and a leading Israeli holding and services group, Cann10 combines the respective expertise in the fields of medical cannabis and commercialization of medical devices and drugs, to support the introduction of new high value related products.

Contact:
Blue Diamond Ventures Inc. / Cann10 North America
535 N. Michigan Avenue, Suite 3001, Chicago, Illinois, 60611
Joshua B. Alper Chief Executive Officer BLDV – Managing Director of Cann10 NA
[phone] [e-mail] www.bldvinc.com

***********End of PR********

Source: https://backend.otcmarkets.com/otcapi/company/dns/news/document/30487/content

- Although this PR does not have any milestone achievement or financing closure updates, I think this PR highlights BLDV's focus on Cann10 and the potential future strategic benefits they will bring to each other. The important PR highlights above that are in red text are pointing to what I think is a more integrated and strategic relationship between BLDV and Cann10.

- As I have stated before in the posts below, I reiterate my thought that Cann10 did not chose to get involved with BLDV for no reason. Cann10 chose BLDV, which is currently an OTC Pink company, to enter North America. You do not see this often with an otc ticker. Notice the "potential of the public aspects" mentioned in the PR - this could be key. Further, if Yossi and Kobi end up joining the BLDV board of directors as stated in the PR above, this could be a good asset for BLDV especially with Yossi sitting on the board of a Nasdaq company.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139016970&txt2find=cann10

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138332570&txt2find=cann10

- The science topics of BioCannacuetical and Biopharmaceutical mentioned in the PR are interesting and it will be important to see how BLDV and Cann10 can possibly succeed using science-based technologies to create revenues and value for the pps. Time will tell.

Go BLDV!